AVDL - Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q3 2021 Results - Earnings Call Transcript

Avadel Pharmaceuticals plc (AVDL) Q3 2021 Earnings Conference Call November 8, 2021 08:30 AM ET Company Participants Courtney Turiano - Investor Relations Gregory Divis - Chief Executive Officer Tom McHugh - Chief Financial Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Vice President of Medical and Clinical Affairs Conference Call Participants Christopher Howerton - Jefferies Francois Brisebois - Oppenheimer & Co. Inc. Ami Fadia - Needham & Co. Rudy Li - SVB Leerink David Amsellem - Piper Sandler & Co. Paul Matteis - Stifel Oren Livnat - H.C. Wainwright & Co. LLC Matthew Kaplan - Ladenburg Thalmann & Co. Inc. Robin Garner - Craig-Hallum Capital Group LLC Jason Gerberry - BofA Securities, Inc. Presentation Operator Greetings and welcome to the Avadel Pharmaceuticals Third Quarter 2021 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Courtney Turiano. Thank you.

For further details see:

Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q3 2021 Results - Earnings Call Transcript